Institutional accumulation regime. Strong business quality combined with supportive market trend. Valuations remain conservative and supported by current metrics.
SENTINEL REVIEW
Anuh Pharma Limited (ANUHPHR)•Updated today
🚨 Structural Deterioration Signature: In FY2026, Anuh Pharma Limited is experiencing severe earnings quality stress, marked by a 13.3% YoY deterioration in reported net profit to ₹41.0 Cr, compounded by a 108.1% YoY contraction in operating cash flow to ₹-3.0 Cr. Profitability is being eroded by intensifying margin compression: EBITDA margins fell to 9.8% from 9.2% YoY, signaling significant operational inefficiency. This operating deterioration is reflected in a severe inventory-revenue divergence: inventory buildup of 25.0% stands against a 7.5% quarterly revenue contraction, contributing to a 61.0 basis point decline in EBITDA margins. Against this liquidity strain, total debt remained nominal at ₹0.0 Cr, but working capital pressure is receding as receivable days increased to 114.8, indicating temporary cash flow friction. Anuh Pharma Limited remains within Flagium’s stable surveillance range, though persistent margin stress and inventory buildup warrant monitoring.
- ✗Risk score deteriorated (QoQ change: +16 pts)
- ✗Profitability margins remain stressed
- ✗New risk trigger: Inventory Stress (+20.2 pts)
- ✓Growth expectations are conservative
- ✓Market structure is strong
- ✓A/D flow regime is Strong Accumulation (1.32σ)
- ✗Share price is down -6.0% this quarter (from ₹87.4 on 30 Sept to ₹82.16)
- 🔴Investigate Industrial Margin Stress and balance sheet impact
- 🟠Track earnings quality and working capital trends in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 11.3 ptsBalance Sheet Stress
- 10.0 ptsGrowth Sustainability
- 14.0 ptsMacro & Sector Calibration
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | +3.03% | +2.9% | +0.13% |
| 1 Month | -6.18% | -3.36% | -2.82% |
| 6 Months | -1.79% | +6.04% | -7.84% |
| 1 Year | -6.78% | +11.85% | -18.63% |
| 2 Year | -26.04% | +45.28% | -71.31% |
| 3 Year | -26.04% | +126.19% | -152.22% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Weakness is detected in balance sheet stress. This suggests a building risk profile. Risk is increasing at a faster pace.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 0 → 35 over 12 quarters.
- Inventory turnover
- Operating profit margins
Risk Drivers (Active Warnings)
Primary Driver & Insights
Asset turnover is slowing down due to inventory accumulation. This indicates potential channel stuffing or weaker demand in core product segments.
Active Risk Objects (4)Free Preview (2 of 4)
Inventory growth (45.9%) significantly outpaced revenue growth (-0.5%).
Slight build-up in inventory detected. Monitor for slowing sales momentum.
ANUHPHR: YoY Inventory growth (+45.9%) outpaced Revenue growth (-0.5%) by +46.4 pp (Inventory holding ratio increased +46.7%).
Slight build-up in inventory detected. Monitor for slowing sales momentum.
Unlock All 4 Forensic Signals (2 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 4 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Anuh Pharma Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Anuh Pharma Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk deteriorated materially (+16.0 pts), driven by new Inventory Stress (+20.2 pts) and Industrial Margin Stress (+1.2 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated notably (+14.0 pts), driven by new Working Capital Expansion (+13.5 pts) and Industrial Margin Stress (+2.4 pts).
Business Resilience & Benchmark Context
Overall: HEALTHYPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Stable
Watch
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Anuh Pharma Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·2 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 |
|---|---|---|
Trade Receivables(₹ Cr) | 239 | 216 |
Inventories(₹ Cr) | 148 | 74 |
Trade Payables(₹ Cr) | 188 | 157 |
Net Working Capital(₹ Cr) | 199 | 134 |
Working Capital / Sales(%) | 25.6% | 19.9% |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 |
|---|---|---|
Cash Conversion Cycle (CCC)(days) | 93d | 73d |
Debtor Days (DSO)(days) | 112d | 117d |
Inventory Days (DIO)(days) | 69d | 41d |
Creditor Days (DPO)(days) | 88d | 85d |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 |
|---|---|---|
Receivable Growth vs Sales (Δ)(%) | -5.1% | — |
Inventory Growth vs Sales (Δ)(%) | +82.7% | — |
Asset Growth vs Sales (Δ)(%) | -5.6% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | 44 | 10 |
Accrual Ratio (Accruals / Avg Assets)(%) | 8.3% | 2.0% |
Operating Cash Realisation (CFO / EBITDA)(%) | -5.6% | 60.9% |
Capitalisation Intensity (CWIP / Assets)(%) | 0.0% | 0.5% |
Industry Intelligence
Pharmaceutical Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
| Q2 FY2027 | 23.7% | +490 bps ↑ Operating efficiency gains | -590 bps ↓ Profitability contraction | 64.0% |
Understanding Pharmaceutical KPIs
Concall & Management Takeaways
Q2-FY27Q2-FY27 Results Published • Concall Ingestion Active
Flagium AI is monitoring regulatory exchange filings (NSE/BSE) for ANUHPHR's official conference call transcript. Executive themes and management tone will automatically appear once filed.
Business quality remains stable.
Current forensic pressure is elevated and stable.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Early Signals and currently deteriorating. Recent structural triggers in balance sheet stress suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Strategic vigilance is advised as structural decay is accelerating.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹82, the market expects this company to grow its revenue by -4.2% every year for the next 5 years. If you think the company will grow faster than -4.2%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market currently expects future growth below the company's historical delivery record. Expectations appear conservative relative to the business's track record, resulting in lower expectation risk.
Using the Implied Revenue Model, the market is pricing ANUHPHR for -4.2% implied revenue growth versus 0.0% observed 3Y revenue CAGR. Current expectations appear conservative, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides limited support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | -4.2% | 0.0% | Achievable |
| Operating Margin (EBIT) | 8.3% | 8.0% | Demanding |
| Free Cash Flow Conversion | -16.7% | 4.0% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance below the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued revenue acceleration, stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 2 advancing phase. Institutional participation has also improved, reinforcing the constructive trend as momentum is accelerating. Current price action continues to support the prevailing advance.
What Is Driving Market Structure?
Price structure remains strong despite building fundamental risk.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & A/D Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on ANUHPHR & 3 market anomalies weekly
See a sample issue →